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TFR2 GENE AND PROTEINS 
Tfr2 is a type II transmembrane glycoprotein, member of the transferrin receptor family and 
homologous to Tfr1 [1]. 
It is encoded by TFR2, a 2471 bp long gene localized on the long arm of human chromosome 7 
(7q22.1), that consists of 18 exons and gives origin to two main variants regulated by different 
specific promoters: Tfr2and Tfr2(Figure 1) 
Tfr2results from the transcription of all exons and is prevalently and highly expressed in 
hepatocytes and erythroid cell lines. Tfr2 cDNA is 2.3 kb long (AF067864) and the Tfr2is a 
protein of about 89 kDa encompassing 801 amino acids [2]. As Tfr1, Tfr2has a short cytoplasmic 
tail (aa 1-80) that contains a consensus sequence YQRV for endocytosis, a transmembrane domain 
(aa 81-104) with four cysteines (aa 89-98 and 108-111), involved in disulphide bonds, likely 
responsible for TFR2 homodimerization, and a large extracellular domain (aa 105-801) comprising 
a protease-associated domain and two RGD motifs that bind di-ferric Tf (Fe2Tf). Furthermore, an 
N-terminal mitochondrial targeting sequence (MTS) has been found in Tfr2 intracellular domain 
[3]. In vitro analysis demonstrated that Tfr2 oncell membrane can be shed and give origin to a 
soluble form and that this process is inhibited by Fe2Tf [4]; however, this form could not be found 
in animal or human sera. 
Tfr2transcription is up-regulated in mouse embryonic fibroblast cells (NIH3T3) by erythroid 
GATA1, EKLF and cEBP/ transcriptional factors, while FOG1 seems to inhibit GATA1 
enhancement [5]. Also, hepatic Hnf4 stimulates Tfr2transcription since it is significantly 
decreased in liver-specific HNF4α-null mice [6]. There is no Tfr2IRE-IRP dependent 
posttranscriptional regulation [7], while the hepatic tetraspanin CD81 is able to interact with Tfr2 
and induce its degradation [8]. 
Tfr2 has an in-frame transcription start site in exon 4, so Tfr2 cDNA (NM_001206855.1) lacks 
exons 1-3 transcript and presents 142 additional untranslated base pairs at its 5' end. Tfr2 is 
ubiquitously expressed at low level, mostly expressed in spleen, heart and brain. The resulting 
protein lacks the cytoplasmic and the transmembrane domain [2]. Since no signal peptide involved 
in secretory pathway could be evidenced in Tfr2 isoform, it is supposed to be a cytosolic 60 kDa 
protein identical to the Tfr2extracellular domain. At the moment, no transcriptional/translational 
regulatory pathway is known for Tfr2isoform (Figure 1). 
 
2 
 
 
Figure 1. Schematic representation of A) TFR2 gene structure. TFR2 18 exons are in bright yellow 
TFR2 promoter is shown upstream the gene and transcriptional factors binding sites are 
highlighted by black arrows. 5’ untranslated region (152 bp long) of TFR2transcript is shown in 
orange; B) the two main transcripts and of Tfr2and Tfr2 isoforms, that are identical in the 
common sequence and the two proteins localization, on the cell surface or in the cytosol 
respectively. 
 
TFR2 and HFE3 
Inactivating mutations of TFR2 gene (OMIM: 604720) lead to type 3 hereditary hemochromatosis 
(TFR2-HHC or HFE3), a rare recessive disorder characterized by increased transferrin saturation 
and serum ferritin concentration and iron overload [9]. 
HFE3 is one of the 5 different forms of hereditary hemochromatosis, a genetically heterogeneous 
disorder due to the deregulation of iron protein Hepcidin (Hepc) [10] (Table1). TFR2-HHC 
presents an earlier age of onset than type 1 hereditary hemochromatosis (HFE-HHC) and some 
pediatric patients have been reported so far. However, the majority of the affected individuals are 
young adults with abnormal serum iron indices [11].  
Most of the mutations involved in HFE3 pathogenesis cause an inactivation of both Tfr2 isoforms, 
but some of them, occurring in exons from 1 to 3, impair the production of only the Tfr2 isoform 
[12-14]. Three patients with homozygote mutation M172K, that impairs Tfr2 translation initiation 
codon were identified, all presenting typical hemochromatosis symptoms (cirrhosis, hypogonadism, 
cardiomyopathy, arthritis) on average age of 38±5 years [13,15]. 
Unfortunately, few clinical data are available on patients with these mutations to allow an 
exhaustive genotype/phenotype analysis. 
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Table 1. HHC types and their relationship with Hepcidin. 
 
 
Systemic Iron Metabolism: the Hepc-Fpn1 axis and the proteins involved in Hepc regulation 
In mammals, the hepatocyte-secreted hormone Hepc regulates systemic iron homeostasis [16]. 
Hepc is codified by HAMP gene, which encodes for an 84 amino acids precursor protein from 
which active 20–25 amino acids peptides are generated [17]. It is expressed primarily in the liver 
although low levels have been also reported in other organs [18]. 
How HAMP gene expression is regulated is mostly unknown. There are no IRE elements in its 
transcript and the transcriptional factor CCAAT/enhancer binding protein-α is highly expressed in 
the liver and seems to stimulate HAMP expression, while the hepatocyte nuclear factor 4-α (HNF-4) 
represses Hepc expression [19]. 
 
The molecular processes involved in hepatic Hepc regulation are quite complex. Basal Hepc 
expression is regulated through the bone morphogenetic protein 6 (Bmp6) and Smad protein 
signalling pathway. In iron excess condition, Bmp6, produced and secreted by liver sinusoidal 
endothelial cells (LSECs) [20], binds to bone morphogenetic protein receptors, ALK2 and/or ALK3 
[21], activin receptor type 2A (Actr2a) [22], Hemojuvelin (Hjv) and Neogenin [23]. The protein 
complex activates signals transducers Smad1/5/8 leading to their interaction with the common 
mediator Smad4. As a consequence of this interplay, Smad4 translocates into the nucleus and 
promotes Hepc transcription [16]. 
 
More recently, it has been demonstrated that bone morphogenetic protein 2 (Bmp2), expressed in 
LSECs, can also trigger Hepc transcription increase [24].  
A second Hepc regulatory pathway involves di-ferric Tf (Fe2Tf) as the signalling of increased iron 
availability, transferrin receptor 1 (Tfr1), hemochromatosis type 1 protein (Hfe) and transferrin 
receptor 2 (Tfr2). It has been demonstrated that Fe2Tf competes with Hfe for binding Tfr1 then, 
when circulating Fe2Tf increases as a consequence of iron raising, Hfe dissociates from Tfr1 and 
binds Tfr2 [25]. Hfe/Tfr2 complex is then responsible for Hepc response to iron increase, through 
the activation of Erk1/2 and MAPK cascade that has been proposed to potentially converge on the 
Bmps/Smad1/5/8 mediated pathway [26]. 
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The hierarchy of the two pathways activation and their relationship are still not completely defined. 
In vitro data support the hypothesis that the complex Hfe/Tfr2 interacts with membrane Hjv (mHjv) 
on cell surface, thereby the link between the two signalling pathways occurs [27]. It has been found 
found in vivo that both Hfe and Tfr2 KO mice present lower pErk1/2 [28] and pSmad1/5/8 proteins 
[29,30], meaning that these two proteins regulate both signal translation pathways. Hepatic Hepc 
up-regulation is inhibited by matriptase 2 (MT-2 or Tmprss6), that acts as Hepc inhibitor cleaving 
mHjv expressed on the plasma membrane [31]. TMPRSS6 gene expression has been found to be 
induced by chronic dietary iron loading and Bmp6 injection [32] and its interaction with Neogenin 
facilitates mHjv cleavage and inactivation in transfected cells [23] (Figure 2). 
 
 
 
Figure 2. Graphic representation of the hepatic Hepc pathway: In condition of systemic iron 
increase. The iron signalling proteins (Fe2Tf and Bmps) interact with iron sensors (Tfr1, Hfe, Tfr2, 
BmpRs) and their co-activator (mHjv) to promote Hepc production. Hepc secreted by hepatocytes is 
transported in plasma and bounds iron exporter Fpn1 on duodenal and reticuloendothelial cells 
surface causing its internalization and intracellular degradation. As a consequence, iron remains 
entrapped in these cells, systemically reducing the metal availability. 
On the contrary, in iron deficiency condition this signalling pathway is inhibited by soluble Hjv 
(sHjv) and Tmprss6, which physically interacts with mHjv causing its fragmentation. 
 
Hepc expression in hepatocytes is systemically regulated by multiple signals: systemic iron 
availability, such as iron loaded transferrin and hepatic iron stores, erythropoietic activity, hypoxia 
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and inflammation [33]. Hepc secreted by hepatocytes regulates iron release from duodenal 
enterocytes, splenic macrophages and hepatocytes, which are responsible for dietary iron 
absorption, contain large amounts of iron from erythrocyte recycling and act as an iron reservoir 
and export iron when needed, respectively. Hepc exerts its function binding the iron exporter 
Ferroportin 1 (Fpn1) [34] and stimulating the complex internalization and degradation, leading de 
facto to cellular retention of iron [35]. Elevated plasma Hepc, as in inflammatory state, 
downregulates iron efflux from several cell types and this leads to an overall reduction in plasma 
iron. On the contrary, low Hepc, as seen in iron-depleted or erythropoietic expansion conditions, 
causes an increased iron release by macrophages and by the basolateral site of villi duodenal cells. 
A potent Hepc inhibitor signal is iron demand for erythropoiesis, mediated by three Hepc 
modulators (Gdf15, Twgs1, Erfe). Their roles and precise mechanisms in Hepc regulation are still 
not completely clear, but Erfe in particular has emerged as a potent Hepc negative regulator in 
condition of acute erythropoietic demand acting in conjunction with erythropoietin (Epo) signalling 
as well as in anemia of inflammation condition [36]. 
HAMP expression is induced by inflammation and infection. This acute phase response involves a 
different pathway from the above described one and is mainly mediated by interleukin 6 (IL-6) 
inflammatory cytokine and requires the signal transducer and activator of transcription 3 (STAT3) 
activation and the binding of STAT3 to a STAT3-binding motif in the Hepc promoter [37]. In 
addition, cytokine IL-22, involved in immunological response to extracellular infections, as well as 
Toll-like receptor 5 (TLR5) agonist flagellin, seem to upregulate Hepc, strengthening the hypothesis 
of a possible Hepc role in innate immunity [38]. 
Conversely, HAMP expression is repressed by hypoxia both in vitro and in vivo in animal models 
[33] and humans [39,40]. The mediator of Hepc response to hypoxia seems to be the hypoxia 
inducible factor (HIF), even though it is not clear if it acts directly or indirectly on Hepc regulation 
[16]. The fact that Hepc inhibitor Tmprss6 presents a hypoxia responsive element (HRE) in its 
promoter [41] might make Tmprss6 the linking protein between hypoxia and iron homeostasis. 
Mutations in HAMP gene and in genes codifying for Hepc regulatory proteins (HFE, TFR2 and 
HJV) cause the lack of up-regulation of Hepc as a response to increased liver iron stores. In fact, 
inappropriately low levels of liver Hepc are observed in patients and mouse models of hereditary 
hemochromatosis [42,43]. These conditions promote a continuous dietary iron absorption that leads 
to iron overload. On the contrary, inappropriately high Hepc has been found in animal models and 
patients with iron resistant iron deficient anemia (IRIDA), a genetic disorder due to mutations in 
TMPRSS6 gene [44-46].  
 
TFR2 IN LIVER 
In the liver, Tfr2 is a sensor of circulating iron, but the knowledge about the Tfr2 hepatic 
function is still incomplete. It is known that Tfr2localizes in caveolar microdomains [47], 
membrane structures involved in the recruitment of receptors that can be activated by ligand 
binding [48]. Also, Tfr2 localizes in lipid raft domains on the exosomal cell membrane where it is 
internalized by clathrin-mediated endocytosis, if transferrin saturation (TS) is low [49].  
Tfr2 protein regulation occurs mainly through its stabilization on the cell membrane as a 
consequence of the binding to Fe2Tf [50,51]. An in vitro study showed that in presence of Fe2Tf, 
Tfr2 has an increased half-life and is recycled, while in presence of apo-Tf membrane Tfr2 is 
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mainly subjected to lysosomal degradation [52]. It has been recently demonstrated that CD81 is also 
able to induce Tfr2 degradation, but the correlation between this Tfr2 regulatory route and Hepc 
pathway is still obscure [8]. 
Therefore, increased TS has an opposite effect on the two Tfrs via two different mechanisms: it 
causes a decrease of Tfr1, regulated by the IRE-IRP system, but a stabilization of Tfr2 on the cell 
surface [1]. 
This supports the hypothesis that Tfr2 exerts its function(s) as a signalling receptor more than as 
an iron importer. 
According to the available in vitro data, hepatic Tfr2 interacts on the cell membrane with two 
main iron proteins, Tfr1 and Hfe. 
The current model assumes that Tfr2, in conjunction with HFE and Tfr1, is partner of a sensor 
complex of circulating iron, that activates Hepc in response to elevated TS [53]. In physiological 
conditions (TS 30-35%) Hfe and the complex Tf/Tfr1 are bound on the plasma cells; when TS 
increases in response to increased iron availability, loaded Tf impairs Hfe binding to Tfr1/Tf 
complex, leading it to bind Tfr2 that is stabilized on the membrane by the same Fe2Tf. The 
resulting complex Tfr2/Fe2Tf/Hfe causes the activation of Hepc transcription [25]. In the HuH7 
hepatoma cells surface, this Tfr2/HFE interaction occurs within a multiprotein complex, that 
includes also mHjv, [27]. It remains to be demonstrated if this complex activates the intracellular 
signalling to up-regulate Hepc expression also in vivo.  
In presence of Fe2Tf, Tfr2 is able to activate Erk1/2 and p38 MAPK kinase signalling 
transduction pathway [47], since Tfr2 KO mice present a decrease of pErk1/2 [28]. Furthermore, 
also Smad1/5/8 pathway seems to be involved in Tfr2 mediated signal transduction, since 
pSmad1/5/8 is decreased in Tfr2 KO animals as well [29].  
Erk 1/2 phosphorylation could be increased also by Hfe overexpression and both Tfr2 and Hfe 
cause an increase of the pro-hormone convertase Furin [29], previously demonstrated to be involved 
in Hepc regulation [54]. Whether it is the sole and/or the main Tfr2 dependent Hepc regulatory 
pathway is still not clear. 
 
TFR2 MOUSE MODELS 
 
The first Tfr2 KO animal model was generated by targeted mutagenesis, introducing a premature 
stop codon (Y245X) in the murine Tfr2 coding sequence [55]. This mutation is homologous to the 
Y250X variant originally detected in humans and responsible for HFE3 [9]. Even young 
homozygous Y245X mice maintained on a standard diet had high liver iron concentration, in 
agreement with the observation of early iron overload in HFE3 patients [11]. As in humans, 
heterozygous animals were normal. The histological distribution of iron resembles the features of 
HFE3, with the typical liver periportal accumulation.  
Subsequently, different murine models of Tfr2 inactivation were developed, including Tfr2 total 
(Tfr2 KO) and liver-specific (Tfr2 LCKO) knock-out [56,57] as well as Tfr2/Hfe double KO [28]. 
All these models are characterized by an inadequate hepatic Hepc expression and liver iron 
overload with variable severity. However, when generated in the same genetic background, Tfr2 
KO mice were shown to have a more severe iron overload than Hfe KO
 
although less severe than 
Tfr2/Hfe double KO [58]. These observations are in agreement with the model of Tfr2/Hfe proteins 
cooperation in the liver.  
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In a double Tfr2/Hjv KO mouse model, plasma Hepc and Hepc transcription was lower than in Tfr2 
and similar to Hjv single KOs respectively. The same was true for the Tfr2/Hfe double KO, [59]. 
Also, a recent study on a mouse model with inactivation of both Bmp6 and Tfr2 (Tfr2/Bmp6 double 
KO) demonstrated that loss of functional Tfr2 further represses Hamp expression, Smad5 
phosphorylation and plasma Hepc amount in Bmp6 KO mice. The same results were obtained in the 
Hfe/Bmp6 double KO and the Hfe/Bmp6/Tfr2 triple KO [60]. All these data support the hypothesis 
that Tfr2 and Hfe act downstream Bmp6 and upstream Hjv in Hepc regulatory pathway. 
Last, Tfr2 germinal vs liver specific KO animals highlighted a distinct function of Tfr2 outside the 
liver in maintaining iron balance. In fact, Tfr2 KO mice have less severe iron overload, slightly 
higher hemoglobin (Hb) levels [57,61] and moderate macrocytosis than Tfr2 LCKO [56,57].  
To study the specific function of Tfr2β isoform in iron metabolism regulation, a specific mouse 
model was generated introducing the M167K substitution in the Tfr2 protein [57]. This mutation, 
homologous to the one found in naturally mutant individuals with HFE3, substitutes the start codon 
methionine of the Tfr2 isoform with a lysine. Interestingly, this knock-in mouse model (Tfr2 KI), 
specifically lacking the Tfr2-isoform (+0) is characterized by normal transferrin saturation, liver 
iron concentration, Hepc and Bmp6 levels, but shows a transient anemia at young age. In additions, 
adult Tfr2 KI animals accumulate iron in the spleen, due to a significant reduction of iron exporter 
Fpn1 mRNA, thus suggesting a possible regulatory effect of Tfr2 isoform on splenic Fpn1 
expression. These data are further supported by the results obtained in Tfr2 macrophage-specific 
KO mouse model. These animals present normal systemic iron parameters but lower Fpn1 transcript 
and protein in peritoneal macrophages [62]. Recent studies demonstrated that Tfr2 is well 
expressed in reticuloendothelial cells of different tissues, where it exerts its role in modulating iron 
availability in these tissues acting on Fpn1 transcription (see below). Since Fpn1 protein has several 
regulatory systems both at transcriptional [63,64] and post-transcriptional level through IRE/IRP 
system [7] and origins from different Fpn1 transcripts with or without IREs [65], it remains to be 
clarified how and when Tfr2 acts on Fpn1 regulation.  
 
TFR2 IN EXTRA-HEPATIC TISSUES 
 
Tfr2 in the erythropoietic compartment  
A Tfr2 erythropoietic role was firstly hypothesized in genome-wide association studies that 
identified Tfr2 polymorphisms affecting hematologic parameters [66,67]. These data were further 
strengthened by the identification of Tfr2 as a component of the Erythropoietin receptor (EpoR) 
complex in erythroid progenitor cells. Tfr2 results to be crucial for efficient transport of EpoR to 
the cell surface and for its terminal differentiation since human erythroid progenitors with silenced 
Tfr2 show a delayed differentiation [68]. Another hint was provided by the increased Hb content 
present only in Tfr2 germinal KO but not in liver-specific KO mice. Since both mouse models 
manifest comparable iron overload, the lack of enhanced hemoglobinization in Tfr2 LCKO mice 
suggests that the erythroid function of Tfr2is preserved [68]. Also, double Tmprss6/Tfr2 KO mice 
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develop erythrocytosis, while in double Tmprss6/Tfr2 LCKO mice, where Tfr2 is functional in 
erythroid cells, RBC number is normal [61]. 
Recently, a mouse model lacking Tfr2 in bone marrow cells (Tfr2
BMKO
) was developed injecting 
BM cells from Tfr2 KO mice in lethally irradiated C57/BL6 mice. Tfr2
BMKO
 mice manifest reduced 
MCV and low Hepc levels as typical response to iron deficiency, but an enhanced terminal 
erythropoiesis showed by increased RBC and Hb content [69]. Interestingly, erythropoiesis and Epo 
level in these mice do not change in a mild dietary restriction setting, as it happens for WT animals, 
where Epo level is drastically increased. 
As a whole, these data suggest that the lack of Tfr2 confers increased Epo sensitivity to erythroid 
progenitor cells, a hypothesis that is further supported by the induction of Epo target genes like 
Hamp regulator Erfe [70] in these animals. 
A similar animal model was recently developed crossing Tfr2 floxed mice with Vav-Cre expressing 
mice to obtain Tfr2 silencing in erythroid compartment [62]. Results differ from the previous work 
since decreased RBC and splenomegaly were observed, but these discrepancies might be explained 
by the different procedures used to create the two mouse models, since in the first case Tfr2 is 
silenced in all bone marrow (BM) cell lines after a BM transplant procedure, while in the latter only 
the erythroid cell line are Tfr2
 
null. 
In another study, Tfr2 erythropoietic role was further investigated studying the erythropoiesis of 
two Tfr2 mice with one or both Tfr2 isoforms silenced (Tfr2 KI and Tfr2 KO) and with normal or 
increased iron availability [57]. The evaluations were performed in bone marrow and spleen, in 
young and adult animals to unravel the erythropoietic role of Tfr2 isoforms at different ages and in 
the two main erythropoietic organs. It resulted that the lack of Tfr2 in Tfr2 KO mice leads to 
macrocytosis with low reticulocyte number and increased Hb value, together with an anticipation of 
erythropoiesis in young mice both in BM and in the spleen [71], probably because the increased 
systemic iron amount present in these animals allows them to reach mature erythropoiesis even at 
young age. 
Although different animals and approaches were used in these studies and the partially 
contradictory results obtained, they all demonstrate that erythropoiesis is impaired by lack of Tfr2 
in BM independently from its activity in hepatic tissues. 
Moreover, results obtained studying Tfr2 KI mice [57] demonstrated for the first time the 
involvement of Tfr2β in favouring iron availability for erythropoiesis. In fact, the sole lack of 
Tfr2β, in normal systemic iron condition, causes an increased but immature splenic erythropoiesis 
seen only in young mice, as if they had insufficient iron availability during animal massive growth, 
that is normalized in animal adult age. Decreased iron availability for erythropoiesis in Tfr2 KI 
young mice is demonstrated by increased ferritin (Ft) and decreased divalent metals transporter 1 
(DMT1) in their splenic monocyte, the increase of Erfe transcription in BM and spleen and the low 
hepatic Hepc transcription that could in turn be responsible of increased splenic Fpn1 amount in 
these animals [71]. 
This effect, due to Tfr2β absence, in aged matched Tfr2 KO () mice was compensated by the 
increased amount of circulating iron available that may be used for erythrocyte production. (Figure 
3A). 
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Figure 3. Schematic model illustrating Tfr2 function in regulation iron export from reticulo-
endothelial (REL) cells. Lack of Tfr2 causes an increased iron retention in REL cells that causes 
(A) the onset of an immature erythropoiesis in the spleen and (B) induces a cardio-protection 
against the effect of the reperfusion of oxygenated solutions after an ischemic event in heart (see 
text). 
 
Tfr2 in the Heart 
The cardiac muscle is a major site of oxygen consumption, so an adequate intracellular iron pool is 
essential to its aerobic activity. This is demonstrated by the finding that deletion of cardiac Tfr1 in 
mice causes fatal energetic failure in cardiomyocytes [72]. Cardiomyocytes express relatively high 
levels of Hepc and Fpn1, despite the fact that these cells have no role in systemic iron control [73].  
Studies on mouse models demonstrated that the cardiac Hepc/Fpn1 axis is essential for heart cells 
autonomous control of the intracellular iron pool that guaranties a normal cardiac functionality [73] 
and that Hepc/Fpn1 appears to protect the heart from the effects of systemic iron deficiency [74].   
On the other side, cardiomyocytes are particularly susceptible to ROS-mediated damage because 
they are rich in mitochondria and consume large amounts of oxygen [75]. Therefore, when labile 
iron pool (LIP) expansion occurs, oxidative stress can affect cardiac functions, as it happens in 
severe juvenile HH forms [10].  
Although ubiquitously expressed, Tfr2β resulted to be highly transcribed in heart [2], so that a role 
for Tfr2β isoform in cardiac iron management has been postulated.  
Indeed, in the hearts of two Tfr2 mice with normal or increased systemic iron amount, Tfr2 KI 
and Tfr2 LCKO[57], the silencing of Tfr2β induces a selective activation of different proteins 
involved in cell survival, antioxidant enzymes, and kinases involved in cardio-protective pathways 
that are usually activated by stressful stimuli. 
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In particular, Tfr2 KI and Tfr2 LCKO mice develop a greater resistance against acute 
Ischemia/Reperfusion (I/R) challenge, irrespective of animals’ systemic iron content, via the 
activation of the RISK or SAFE/GSK3 cardio-protective pathway respectively. The iron 
imbalance present in these mice hearts was demonstrated by the finding that both the models 
present the activation of antioxidant proteins, pro-apoptotic markers and catalase even before I/R 
[76]. They also have a slightly increased synthesis of cardiac ferritins, similarly to what happens in 
ischemic preconditioning, in which a small increase of ferritin protects cardiac cells from iron-
mediated oxidative damage associated with ischemia-reperfusion injury [77]. 
Since previous data demonstrated a significant decrease of Fpn1 and an increased iron deposit in 
splenic macrophages in Tfr2β null mice [57,71], one might hypothesize that Tfr2β isoform 
inactivation in the heart causes an iron retention in cardiac reticuloendothelial cells, that is able to 
induce cardio-protective pathways activation and to reduce iron availability to form free oxygen 
radicals during the reperfusion phase (Figure 3B). 
 
Tfr2 in the Central Nervous System (CNS) 
Iron levels in the brain varies during life: iron amount increase with aging in the striatum and the 
brain stem [78]; it is present in most CNS cell types, neurons, oligodendrocytes, microglia and 
astrocytes [79]. A well-regulated iron homeostasis is important for brain development and function. 
Iron deficiency negatively impacts neurodevelopmental processes [80] and is also implicated in a 
number of psychiatric and neurological conditions, learning disabilities, attention deficit 
hyperactivity disorder (ADHD) and pediatric restlessleg–syndrome (RLS) [81,82]. On the contrary, 
brain iron overload is present in Alzheimer’s and Huntington’s neurodegenerative disorders as well 
as in Parkinson disease (PD). Nevertheless, the exact role of iron in these diseases onset/worsening 
is still debated and it remains to be clarified whether brain iron overload is directly involved in their 
pathogenesis or it is a secondary effect that contributes to their clinical symptoms progression. 
The main sites of brain iron uptake are the brain vascular endothelial cells (BVECs) present in the 
blood-brain barrier (BBB) [84]. As in other organs, there are two main pathways responsible for 
CNS cells iron uptake, the Tf-Tfr1 pathway, and the NTBI transport pathway. Traditionally, Tf-
Tfr1 is considered a major pathway and works as in all the other cell types of the organism, through 
a receptor mediated endocytosis of plasma Tf circulating in the ventricles [85].  
The NTBI transport pathway has been recently revaluated as a significant way to introduce iron in 
CNS and it could be done through vesicular or non-vesicular mechanism. In the first case Tf 
homologues, as lactoferrin and melanotransferrin, might be involved in Tfr mediated iron transport; 
moreover, the newly characterized Ft receptors Tim 2 and Scara5 can introduce iron inside the cells 
through a Ft-FtR pathway. Non vesicular iron uptake can be exerted by iron importer DMT1, that is 
present in endothelial cells of the brain microvasculature, as well as other importer like IN4/5/6 
[86].  
In CNS, iron exporter Fpn1 is found in BVECs, neurons, oligodendrocytes, astrocytes, the choroid 
plexus, and ependymal cells and microglia together with ceruloplasmin (CP) or hephestin (Hp), the 
two ferroxidases that cooperate with Fpn1 to facilitate iron export [87]. Fpn1 could be the main 
responsible for iron release from CNS cell, even if other proteins and mechanism have been brought 
into play for these processes [86].  
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Inside brain cells, the majority of iron is bound to ferritin heteropolymers (Ft H/L) [88]. Their 
cellular distribution and ratio varies with iron status, age, and disease conditions [89]. 
CNS iron homeostasis is intracellularly modulated by (IRE/IRPs) system [90] and by local and 
systemic Hepc. Injection of Hepc into the mouse lateral cerebral ventricle decreases Fpn1 protein 
levels and treatment of primary cultured rat neurons with Hepc decreases Fpn1 expression and 
results in the subsequent release of iron [91]. More recently, it was demonstrated that injection of 
adenovirus expressing Hepc (ad-hepcidin) in brain ventricles reduces brain iron in iron-overloaded 
rats through the downregulation of iron transporter [92]. This data indicates that Hepc/Fpn1 axis is 
present and acts in CNS as in the other districts of the organism. 
It remains a matter of debate whether Hepc acting on brain is locally produced or comes from the 
systemic circulation crossing the BBB or both [93]. 
Similar to other Hepc regulatory proteins, Tfr2 gene expression has been shown in total brain 
extracts [2,94], in brain tumor cell lines [95] or in specific neuronal subtypes as dopaminergic 
neurons [3]. Furthermore, a transcriptome study on Tfr2 null mice revealed that several genes 
involved in the control of neuronal functions are abnormally transcribed [96]. Noteworthy, the same 
experimental approaches applied to Hfe null mice, revealed that a consistent percentage of 
transcripts are modified in the same way in the two models [96]. This highlights the possibility of a 
cooperation between Tfr2 and Hfe protein in CNS iron regulation as in the rest of the organism. 
Immunofluorescence studies using a Tfr2 specific antibody demonstrate that the protein is 
significantly produced in mouse hippocampus, amygdala, central nucleus, and in the hypothalamic 
paraventricular nucleus [97]. 
A recent study assessed the situation of iron in the brain of Tfr2 KO mouse model vs WT sib pairs 
submitted to an iron enriched diet (IED). They both are iron overloaded animals so one could 
distinguish the effects of Tfr2 silencing from those due to Tfr2-independent iron load modifications. 
It has been demonstrated that Tfr2 causes a lack of brain Hepc response to the systemic raise of iron 
levels, with altered iron mobilization and/or cellular distribution in the nervous tissue [98].  
Moreover, Tfr2 KO mice present a selective over activation of neurons in the limbic circuit and the 
emergence of an anxious-like behaviour.  
Also, microglial cells showed sensitivity to iron perturbations of Tfr2 KO mice, being more 
reactive, dystrophic and with a high level of apoptosis [97]. In light of these data, Tfr2 appears to be 
a key regulator of brain iron homeostasis and could have a role in the regulation of the brain regions 
that are involved in the anxiety onset, mainly the basolateral and central nucleus subregions of the 
amygdala [98]. 
 
TFR2 IN INTRACELLULAR IRON TRAFFICKING 
It is still under debate if Tfr2contributes to iron introduction inside the cells. When the protein 
was characterized, it was reported that in vitro was able to introduce iron inside cells [2], but its 
contribution to intracellular iron amount in vivo seems to be quite negligible, since Tfr1 deficient 
mice present severe iron deficiency not compensated by the presence of Tfr2 [1]. 
Conversely, Tfr2 seems to have a role in intracellular iron trafficking, at least in specific cell 
types. The first evidence about it was found in dopaminergic neurons, where a novel Tf/Tfr2-
mediated iron transport pathway to the mitochondria has been reported [3]. Disruption of this 
12 
 
Tf/TfR2-dependent system has been associated with PD, this finding highlighs the role of iron 
accumulation in this movement disorder [3]. In this regard, protective association between some Tf 
and TfR2 genetic haplotypes and PD was reported, suggesting that Tf or a Tf/TfR2 complex may 
play a role in the etiology of this disorders [99]. 
More recently, a similar TfR2 function in iron delivery to mitochondria has been convincingly 
demonstrated in erythroid cells. In intermediate stage of human erythroid cells maturation, Tfr2 
results to be present in cytoplasmic multi-organelles complexes formed by lysosomes surrounded 
by mitochondria and to be co-regulated with several proteins among which ionic channels and 
proteins involved in lysosomal modification and in mitochondrial membrane contacts to other 
intracellular organelles [100]. Therefore, Tfr2evidenced in lysosomes has been proposed to be 
involved in iron delivery from these organelles to mitochondria for Hb synthesis. Considering the 
above mentioned evidence about a specific role of Tfr2 in erythropoiesis, this data might represent 
one of the molecular processes at the basis of Tfr2erythropoietic function/s. (Figure 4). 
 
 
Figure 4. Schematic model illustrating the putative intracellular Tfr2role in erythroid cells. 
Tfr2 together with ATPV0C, aV-ATPase that contributes to vesicular acidification and lysosomal 
activity, Mcoln1, a lysosomal divalent cation channel, lysosomal cathepsin B (CTSB) and iron 
importer DMT1 could be involved in iron delivery from lysosome to mitochondria, with the 
collaboration of Mitofusin-2 (MFN-2), a mitochondrial outer membrane protein involved in 
mitochondria-endoplasmic reticulum contacts. 
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On the light of the above data, Tfr2involvement in iron delivery to the mitochondria notably 
seems to work at least in the two compartments in which this protein is significantly produced, 
brain and bone marrow. Although a similar mechanism has been evidenced also in cell lines derived 
from other organs (HeLa and hepatoma cell lines) [52,101], it remains an open question if this 
TfR2 function is present also in other cell types  
 
TFR2 IN OTHER DISEASES 
Being a “regulator of the iron regulator” Hepcidin, Tfr2 transcriptional analysis was attempted to 
unravel if the Tfr2 isoforms could be reliable markers for some disorders in which iron 
perturbations occur. 
Tfr2 in cancer 
Cancer cells need increased amount of iron for their growth and iron importers up modulation 
confer to these cells a selective advantage.  
Since its characterization, the significant transcription of TFR2 gene appeared evident in BM cancer 
cells, in particular erythroid leukemic cells [5], but also in myeloid malignant cells [2], while Tfr2 
seemed much more prevalent than the TfR2 isoform in chronic B cells lymphocytic leukemia (B-
CLL) [102]. 
Due to high TFR2 expression in erythroid lineage and to its functional relationship with the 
erythropoietin receptor (EpoR) [68], TFR2 transcription was evaluated in patients with 
myelodysplastic syndromes (MDS), a hematopoietic disorder with a variable risk to evolve in acute 
leukemia (AML) and in which chronic anemia can be corrected by Epo injection [103]. It has been 
found that Tfr2 and Tfr2isoforms, as well as EPOR transcript, have lower level of transcription 
in BM from high risk MDS patients, such as RAEB2, compared to controls and low risk MDS cells 
[104]. Likewise, AML patients with high level of Tfr2 and Tfr2 present an increased survival 
[105]. Therefore, Tfr2 isoforms might represent good predictive markers for MDS/AML prognosis. 
Calzolari et al. 2007 [106] demonstrated TFR2 expression in colon and ovarian cancer cell lines as 
well as in lymphoma and glioblastoma (GBM). Moreover, in glioblastoma TB10 cell line under 
hypoxic condition, a marked increase of TFR2 transcription was observed. In these cell lines, TFR2 
high expression is probably correlated with cells proliferation, since Tfr2 silencing inhibited GMB 
cells growth. Surprisingly, tumor cells from GBM patients with high TFR2 transcriptional levels 
present a better prognosis compared to patient with low transcripts. Although, this is probably due 
to the fact that the highly increased Tfr2 expressing cells proliferate so are more sensitive to 
tomozolomide, the anti-proliferative drug used in GBM therapy, more than to a direct involvement 
of Tfr2 in the disease course [107]. 
 
Tfr2 in Alzheimer disease (AD) 
Alzheimer disease (AD) is another common degenerative disorder in which iron perturbation has 
been demonstrated [108]. 
A recent genetic study from 116 AD patients has found that a Tfr2 single nucleotide polymorphism 
(rs 7385804) and a Tfr2 haplotype, composed by two SNPs (rs 7385804 and rs 4434553) are 
associated with a decreased AD susceptibility [109]. 
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In the same study, a significant decrease of Tfr2 transcription was found in peripheral blood 
mononuclear cells (PBMC) from AD patients compared to healthy controls (p<0.001) [110]. 
 
TFR2 AS A THERAPEUTIC TARGET 
In our opinion, three might be the major application of Tfr2as a therapeutic target: a) as Hepc 
regulator it could be a target in disorders in which Hepc amount is in someway inadequate to body 
iron availability; b) since Tfr2 production is selective in specific organs and cell types, it could 
represent a selective target to correct iron perturbation in these organs; c) being Tfr2 a membrane 
protein that is able to link plasma Tf and to be internalized with it, this property could be utilized as 
a vector for drugs.  
As mentioned above, TfR2 is involved in regulation of Hepc and, in consequence, in iron 
modulation according to body/organs needs. Among the Hepc related disorders there are all the 
hereditary hemochromatosis forms (Table 1) and the secondary iron overload disorders like 
hemoglobinopathy, where abnormally low Hepc amount leads to iron overload. 
In this regard, just published data demonstrate that Tfr2 KO BM transplantation in a Beta-
thalassemia intermedia (β-TI) mouse models significantly improved these animals erythropoiesis, 
opening a new way to the therapy of this very common disorder [111]. 
In IRIDA and anemia of chronic disease (ACD), where abnormally high Hepc causes the onset of 
an iron deficiency condition [111], Tfr2 down-modulation might be beneficial to decrease Hepc 
hyper-production. A preliminary study on mice revealed that Tfr2 silencing through small 
interfering RNAs (Tfr2-siRNA) in a single dose led to a significant Hepc down-modulation and 
increase transferrin saturation within 24 hours post-administration, persisting for more than two 
weeks, and to recovery from anemia in animal models of ACD [112]. 
Beside the liver, in brain Tfr2 regulates the production of local Hepc and iron amount in the CNS 
since Tfr2 KO mice brain have a blunted Hepc response to brain iron overload [97]. In recent time, 
it has emerged that brain Hepc production is altered in several neurodegenerative disorders: down-
modulated in Alzheimer and Parkinson disease [113,114] and up-modulated in restless legs 
syndrome (RLS) [115]. It might be worthwhile to further investigate if Tfr2 is involved in these 
Hepc variations and consider using anti Tfr2 antibodies or siRNA based therapy to rescue Hepc 
physiologic values in RLS. Nowadays siRNA delivery to brain is quite difficult due to the presence 
of BBB, but the ongoing studies on nanoparticles use to target siRNA in specific sites could allow 
to increase the efficacy of this therapy [116]. 
An alternative therapeutic approach aims to deliver blocking antibody in the brain exploiting the 
BBB physiologic activities. It is based on the use of anti-Tfr1 antibodies, since Tfr1 well expressed 
in BBB endothelial cells and is involved in receptor-mediated transcytosis. Indeed, it has been 
demonstrated that the bispecific Tfr1/BACE1 (-amyloid cleaving enzyme-1) antibody resulted to 
be effective in decreasing -amyloid concentration in brain [117]. 
Due to Tfr1/Tfr2 high homology and the common cellular internalization through a receptor 
mediated endocytosis pathway, one could hypothesize a parallel Tfr2 based approach for CNS 
blocking antibody delivery. Nevertheless, it should be further confirmed Tfr2 presence on BBB 
endothelial cells and its involvement in transcytosis. 
 
15 
 
Recent studies have aimed at exploiting the Tfr1 as a vehicle for drug delivery inside the cells 
through endocytosis, often utilizing Tfr1 natural ligand, Tf, conjugated with different synthetic 
molecules [1]. Moreover, since Tfr1 is able to bind and internalize FtH also [118], FtH nanocages 
conjugated with a PARP inhibitor, olaparib, was developed for breast cancer therapy [119]. 
Due to its strict homology to Tfr1, one might hypothesize that Tfr2 could also be utilized to 
deliver drugs inside cells. This approach would be particularly useful for two main Tfr2 features; 
Tfr2selective expression in particular tissues (hepatic, erythroid and in CNS) and Tfr2high 
expression in several tumor cells, sometimes with Tfr1 and sometimes without it. High expression 
of Tfr1 and Tfr2 were in fact detected in tumor and para-cancerous normal liver tissues collected 
from 41 patients with hepato cellular carcinoma (HCC) [120]. Tfr2 is also highly expressed in 
brain tumor cells in several cases of anaplastic astrocytoma and glioblastoma, but not in normal 
brain or endothelial brain cells [121].  
Furthermore, on the light of the new data on Tfr2 function in delivery iron to mitochondria, Tfr2 
could possibly represent a good vehicle for drug delivery in these organelles [122], paving the way 
to tailored therapies for mitochondrial iron unbalanced disorders, notably Friederich Ataxia [123]. 
Unfortunately, too few functional data are available at the moment on Tfr2 isoform to foresee 
possible therapeutic applications. 
 
CONCLUSIONS  
The process of body iron homeostasis is complex, and since there is no apparent significant 
excretory pathway, the amount of iron absorbed from mature duodenal enterocytes and that 
recycled by macrophages need to be tightly regulated. From the last decades, iron pathways have 
been enriched of new regulatory proteins whose functions remains to be elucidated from the 
molecular point of view. Each of them could represent a potential target for a focused 
pharmacological therapy of disorders with iron unbalance, that still represent the most prevalent 
diseases all around the world. 
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